We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Diffuse PRAME expression is highly specific for malignant melanoma in the distinction from clear cell sarcoma.
- Authors
Raghavan, Shyam S.; Wang, Jennifer Y.; Toland, Angus; Bangs, Charles D.; Rieger, Kerri E.; Novoa, Roberto A.; Charville, Gregory W.; Brown, Ryanne A.
- Abstract
Preferentially expressed antigen in melanoma (PRAME) is a tumor-associated antigen that was first identified in T-cell clones of patients with malignant melanoma (MM).1 Gene expression profiling performed by Clarke I et al i . identified PRAME upregulation in MM relative to nevi, and this finding was later confirmed by Mitsui I et al i .2,3 More recently, Lezcano I et al i . reported diffuse immunoreactivity for PRAME in 87% of metastatic and 83.2% of primary MM.4 Clear cell sarcoma (CCS), also known as malignant melanoma of soft parts, can be histopathologically indistinguishable from MM. Prototypical features of CCS include spindled-to-epithelioid tumor cells with clear or lightly eosinophilic cytoplasm and oval nuclei with prominent nucleoli arranged in fascicles and/or nests with intervening fibrous septa. One melanoma demonstrated weak expression in 5% of cells and another melanoma showed no PRAME expression.
- Subjects
MELANOMA; SARCOMA; DYSPLASTIC nevus syndrome; FLUORESCENCE in situ hybridization
- Publication
Journal of Cutaneous Pathology, 2020, Vol 47, Issue 12, p1226
- ISSN
0303-6987
- Publication type
Article
- DOI
10.1111/cup.13812